Humankind Investments LLC Boosts Holdings in Edwards Lifesciences Co. (NYSE:EW)

Humankind Investments LLC increased its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 7.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,972 shares of the medical research company’s stock after acquiring an additional 473 shares during the quarter. Humankind Investments LLC’s holdings in Edwards Lifesciences were worth $516,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Norges Bank acquired a new position in Edwards Lifesciences during the fourth quarter worth approximately $610,895,000. Jennison Associates LLC acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at approximately $555,939,000. Vanguard Group Inc. grew its position in shares of Edwards Lifesciences by 10.4% during the fourth quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company’s stock worth $5,117,845,000 after acquiring an additional 6,537,494 shares during the last quarter. Assenagon Asset Management S.A. increased its holdings in shares of Edwards Lifesciences by 475.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company’s stock valued at $314,182,000 after acquiring an additional 3,506,886 shares during the period. Finally, Raymond James Financial Inc. purchased a new stake in Edwards Lifesciences in the 4th quarter valued at $213,844,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Trading Down 1.1 %

NYSE:EW opened at $73.82 on Friday. The company has a market capitalization of $43.40 billion, a PE ratio of 10.59, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $95.25. The stock has a fifty day simple moving average of $71.48 and a 200-day simple moving average of $71.50. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.60 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The company had revenue of $1.41 billion for the quarter, compared to the consensus estimate of $1.40 billion. During the same quarter in the prior year, the firm earned $0.66 earnings per share. The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. On average, equities research analysts expect that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 11,250 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $75.76, for a total transaction of $852,300.00. Following the sale, the chief financial officer now owns 30,561 shares in the company, valued at approximately $2,315,301.36. This trade represents a 26.91 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Steven R. Loranger sold 5,739 shares of Edwards Lifesciences stock in a transaction on Friday, February 14th. The shares were sold at an average price of $76.42, for a total value of $438,574.38. Following the completion of the sale, the director now directly owns 60,372 shares of the company’s stock, valued at approximately $4,613,628.24. This represents a 8.68 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 89,681 shares of company stock worth $6,492,703. 1.29% of the stock is owned by insiders.

Analyst Ratings Changes

EW has been the topic of several research reports. Canaccord Genuity Group raised their price objective on shares of Edwards Lifesciences from $71.00 to $75.00 and gave the stock a “hold” rating in a research report on Friday, April 25th. Truist Financial dropped their price target on Edwards Lifesciences from $78.00 to $75.00 and set a “hold” rating on the stock in a research report on Friday, April 11th. Evercore ISI decreased their price objective on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a research report on Wednesday, February 12th. Royal Bank of Canada reiterated an “outperform” rating and issued a $85.00 target price on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. Finally, Stifel Nicolaus raised Edwards Lifesciences from a “hold” rating to a “buy” rating and increased their price target for the stock from $75.00 to $90.00 in a report on Thursday, January 30th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating and twelve have given a buy rating to the stock. According to MarketBeat.com, Edwards Lifesciences currently has an average rating of “Hold” and a consensus target price of $79.45.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.